Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
MALVERN, Pa., April 25, 2017 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Vice President of Research & Scientific Affairs Jim Ballance, Ph.D., will present preclinical and clinical data on the company’s proprietary elastin-like polypeptide (ELP) biopolymer technology platform in an oral session at the TIDES: Oligonucleotide & Peptide Therapeutics conference to be held April 30 - May 3 at the Manchester Grand Hyatt in San Diego, CA.
Details on the presentation are as follows:
Title: Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides
Track: Peptide Discovery, Preclinical and Clinical
Session: Peptides in the Clinic: Lessons Learned
Date / time: Tuesday, May 2, 3:05 - 3:30 p.m. PDT
Location: Cortez Hill
For additional information on the conference, please visit: https://lifesciences.knect365.com/tides/.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
